Monash IVF Group Ltd (MVF) AI Stock Analysis

• Market Cap: AU$294.17M
• Dividend Yield: 6.75%
• Average Volume (3M): 2.07M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.72
• Revenue Growth: 14.24%
• EPS Growth: -109.59%
• Country: AU
• Employees: 997
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.04
• Shares Outstanding: 389,634,830
• 10 Day Avg. Volume: 1,849,275
• 30 Day Avg. Volume: 2,068,949
• PEG Ratio: -2.48
• Price to Book (P/B): 1.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 24.81
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$1.13
• Price Target Upside: 52.70% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 48 Neutral
• Price Target: ―

Monash IVF Group Ltd's stock faces significant challenges, primarily due to operational losses and negative profitability, as reflected in the financial performance and valuation metrics. Despite strong revenue and cash flow growth, the company's technical indicators suggest bearish momentum. The high dividend yield offers a cushion, but the stock's attractiveness is limited by its current financial struggles.

Monash IVF Group Ltd Business Overview & Revenue Model

Company Description

Monash IVF Group Ltd (MVF) is a leading reproductive health care provider, primarily operating in Australia and Southeast Asia. The company specializes in assisted reproductive services (ARS), including in vitro fertilization (IVF), genetic testing, ultrasound, and other related fertility treatments. Monash IVF Group is renowned for its cutting-edge technology and research-driven approach, offering comprehensive support to individuals and couples facing fertility challenges.

How the Company Makes Money

Monash IVF Group Ltd generates revenue primarily through its assisted reproductive services, with in vitro fertilization (IVF) being the core offering. The company also earns income from ancillary services such as genetic testing, fertility consultations, and diagnostic imaging. These services are typically provided through a network of clinics, which are staffed by specialized medical professionals. Monash IVF Group further benefits from partnerships with healthcare providers and insurance companies, which can facilitate patient referrals and payments. Additionally, the company's focus on research and innovation helps maintain its competitive edge in the market, thereby attracting more clients seeking advanced fertility solutions.

Monash IVF Group Ltd Financial Statement Overview

Summary

Monash IVF Group Ltd shows mixed financial health. Despite robust revenue growth and strong cash flow generation, the company faces profitability challenges with recent operational losses. Its balance sheet shows moderate leverage, which requires monitoring. The company needs to focus on improving operational efficiencies to turn revenue growth into sustainable profits.

Income Statement

The income statement shows cause for concern with a negative EBIT and net income for the most recent year, indicating operational losses. Revenue growth rate was strong at 19.4% compared to the previous year, but this has not translated into profit growth due to higher costs. Gross profit margin stands at 33.5%, down from previous years, indicating increased cost pressures.

Balance Sheet

The balance sheet reveals a stable equity base with stockholders' equity at 47.6% of total assets. However, the debt-to-equity ratio is relatively high at 0.56, suggesting moderate leverage. Return on equity has turned negative due to the net loss, which is a risk factor.

Cash Flow

Cash flow is a bright spot with a strong operating cash flow to net income ratio, indicating good cash generation relative to net income. Free cash flow grew significantly by 203.6% year-over-year, highlighting effective capital expenditure management. However, the net loss casts a shadow on future cash flow sustainability.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
269.91M	254.96M	213.59M	192.29M	183.60M	145.42M
	Gross Profit
89.82M	85.50M	63.41M	57.22M	57.66M	38.37M
	EBIT
2.15M	-5.61M	35.04M	30.91M	35.12M	16.93M
	EBITDA
11.50M	13.03M	48.49M	45.69M	51.21M	32.84M
	Net Income Common Stockholders
-2.29M	-6.53M	21.84M	18.41M	25.15M	11.73M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
5.93M	11.33M	8.01M	7.87M	8.76M	15.07M
	Total Assets
450.14M	508.47M	421.89M	387.10M	356.17M	354.22M
	Total Debt
121.74M	135.37M	100.04M	77.23M	45.99M	57.57M
	Net Debt
115.81M	124.04M	92.03M	69.36M	37.23M	42.50M
	Total Liabilities
169.32M	261.81M	146.82M	117.20M	87.73M	102.10M
	Stockholders Equity
276.44M	241.91M	273.20M	267.92M	266.19M	249.81M
Cash Flow		Free Cash Flow
13.11M	30.85M	10.16M	19.51M	33.30M	19.04M
	Operating Cash Flow
29.46M	52.52M	37.95M	31.28M	43.25M	26.54M
	Investing Cash Flow
-31.36M	-38.80M	-40.51M	-15.16M	-11.21M	-9.26M
	Financing Cash Flow
4.78M	-10.39M	2.68M	-17.02M	-38.35M	-6.46M

Monash IVF Group Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.74
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MVF, the sentiment is Negative. The current price of 0.74 is below the 20-day moving average (MA) of 0.80, below the 50-day MA of 0.86, and below the 200-day MA of 1.09, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 36.50 is Neutral, neither overbought nor oversold. The STOCH value of 7.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:MVF.

Monash IVF Group Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SHL	72 Outperform	AU$12.71B	23.22	6.86%	4.04%	10.15%	6.20%
RHC	66 Neutral	$8.73B	1,067.13	0.52%	2.20%	7.25%	-99.04%
Sector *	54 Neutral	$5.31B	3.29	-45.39%	2.79%	16.77%	-0.07%
IDX	51 Neutral	AU$871.49M	96.30	1.14%	2.48%	7.83%	―
MVF	48 Neutral	AU$294.17M	―	-0.87%	6.75%	14.24%	-109.59%
HLS	45 Neutral	€602.69M	―	-4.46%	―	-7.82%	98.08%

Monash IVF Group Ltd Corporate Events

Monash IVF Group Revises FY2025 Profit Guidance Amid Challenging Market Conditions

Monash IVF Group Limited has revised its profit guidance for the fiscal year ending June 2025, now expecting an underlying NPAT of approximately $27.5 million, down from the previously anticipated $30.0 million to $31.0 million. This adjustment is due to softer market and operating conditions experienced in March and April 2025, although some recovery was noted in May. The company is also monitoring potential impacts from a recent incident in Brisbane, which could affect patient registrations and other operational metrics.

The most recent analyst rating on (AU:MVF) stock is a Buy with a A$1.55 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.

Monash IVF Addresses ASX Inquiry on Isolated Incident

Monash IVF Group Ltd responded to an ASX inquiry regarding an incident of human error, which they consider isolated and not materially affecting their financial performance for FY2025. The company has initiated an independent investigation to address the incident responsibly, and while the announcement was marked as market sensitive due to its financial commentary, MVF maintains that the information was not initially disclosed as it was not deemed obligatory under listing rules.

UniSuper Ceases Substantial Holding in Monash IVF Group

Monash IVF Group Limited has announced that UniSuper Limited, acting as trustee for UniSuper and UniSuper Management Pty Limited, has ceased to be a substantial holder in the company as of April 11, 2025. This change in substantial holding could impact the company’s shareholder structure and influence its market dynamics, as substantial holders often play a significant role in company decisions and stock performance.

Soul Patts Increases Stake in Monash IVF Group

Monash IVF Group Ltd, a company listed on the Australian Securities Exchange (ASX: MVF), has seen a change in the substantial holding by Washington H. Soul Pattinson and Company Limited (Soul Patts). Soul Patts has increased its voting power in Monash IVF Group from 6.28% to 9.69%, reflecting a significant acquisition of shares. This change in shareholding indicates a stronger influence by Soul Patts in the company’s decision-making process, potentially impacting the strategic direction and operations of Monash IVF Group.

Monash IVF Investigates Embryo Transfer Incident at Brisbane Clinic

Monash IVF Group Limited has confirmed an incident at its Brisbane clinic where an embryo was incorrectly transferred between patients, resulting in the birth of a child. The company is conducting an independent investigation led by Fiona McLeod AO SC to identify further safeguards and is committed to implementing all recommendations. Despite the incident, Monash IVF does not consider it material to its FY2025 financial performance and has informed relevant regulatory bodies and its insurers.

UniSuper Acquires Substantial Stake in Monash IVF Group

UniSuper Limited, as trustee for UniSuper and UniSuper Management Pty Limited, has become a substantial holder in Monash IVF Group Ltd, acquiring a 5.04% voting power through 19,626,468 ordinary shares. This acquisition signifies UniSuper’s strategic interest in Monash IVF, potentially impacting the company’s shareholder dynamics and market positioning.

UniSuper Ceases Substantial Holding in Monash IVF Group

UniSuper Limited, acting as trustee for UniSuper and UniSuper Management Pty Limited, has ceased to be a substantial holder in Monash IVF Group Ltd as of March 11, 2025. This change in substantial holding reflects a shift in UniSuper’s investment strategy, potentially impacting Monash IVF’s shareholder composition and market perception.